Nivolumab use in Hodgkin’s Lymphoma after Allogeneic Hematopoietic Cell Transplantation

At ASH 2015, Dr. Charles Herbaux discusses his abstract titled "Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC."
For more oncology news, education, and information, please visit http://www.oncology.tv/